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Background: Many clinical trials had repeatedly shown that fast-track perioperative care and laparoscopic surgery
are both preferred in the treatment of colorectal cancer. But few studies were designed to explore the diverse
biochemical impacts of the two counterparts on human immunologic and nutritional status.
Methods: Ninety-two cases of colorectal cancer patients meeting the inclusion criteria were randomized to four
groups: laparoscopy with fast-track treatment (LAFT); open surgery with fast-track treatment (OSFT); laparoscopy
with conventional treatment (LAC); open surgery with conventional treatment (OSC). Peripheral blood tests
including nutritional factors (albumin, prealbumin, and transferrin), humoral immunologic factors (IgG, IgM, and IgA),
and cellular immunologic factors (T and NK cells) were evaluated. Blood samples were collected preoperatively
(baseline) and 12 and 96 h after surgery (indicated as POH12 and POH96, respectively).
Results: Albumin, transferrin, prealbumin, and IgG levels were the highest in the LAFT group for both POH12 and
POH96 time intervals. Repeated measures (two-way ANOVA) indicated that the difference of albumin, transferrin,
and IgG level were attributed to surgery type (P < 0.05) and not perioperative treatment (P > 0.05). Only in the
laparoscopy-included groups, the relative albumin and IgG levels of POH96 were obviously higher than that of POH12.
Conclusion: Laparoscopic surgery accelerated postoperative nutrition and immune levels rising again while
fast-track treatment retarded the drop of postoperative nutrition and immune levels. Laparoscopic surgery might
play a more important role than fast-track treatment in the earlier postoperative recovery of nutritional and
immunologic status. Combined laparoscopic surgery with fast-track treatment provided best postoperative
recovery of nutrition and immune status. These results should be further compared with the clinical outcomes of
our FTMDT trial (clinicaltrials.gov: NCT01080547).
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In the past few years, the introduction of two feasible
treatments, the fast-track recovery program after surgery
[1] and laparoscopic surgery, has been proved to signifi-
cantly benefit patients. Many clinical trials have indicated
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unless otherwise stated.duration of paralytic ileus, and reduction in deterioration
of vital organs when compared with patients undergoing
conventional perioperative care and open surgery [2-4].
But many of the above trials only concerned the clinical
impact of the fast-track care and laparoscopy, respectively;
extremely few studies were designed to explore the bio-
chemical impacts on human immunity and nutrition
when combined fast-track care with laparoscopic tech-
niques. And it still remained unclear that how much of
the clinical benefit was due to laparoscopy and how much
was an effect of different perioperative care [5].is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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combined treatment of laparoscopic colostomy and fast-
track care. According to the results from LAFA trial, the
optimal combination of treatment for colon cancer pa-
tients is a laparoscopic surgery combined with a fast-track
perioperative care [6,7]. And among colorectal patients,
the EnROL trial also indicated laparoscopic surgery con-
fers a significant clinical benefit versus open surgery em-
bedded in an enhanced recovery program [8]. According
to our previous study, we have registered and reported a
2 × 2 randomized controlled trial focusing on multi-
discipline approach to implementation of a fast-track
program (The Fast Track Multi-Discipline Treatment—
FTMDT trial, clinicaltrials.gov: NCT01080547). The op-
erable protocol of the FTMDT trial had been published
[9], and the further research program concerned two direc-
tions were carried out. Direction 1 concerned more about
the clinical parameters of patients such as hospitalization
stay, return of bowel movement, etc. while direction 2
followed closely the detailed and biochemical impacts of
the combined treatment of laparoscopic colostomy and
fast-track perioperative treatments.
Albumin, prealbumin (PAB), and transferrin (TRF) are
commonly called as “hepatic proteins” that are synthe-
sized in the liver. By evaluating the levels of serum albu-
min, PAB, and TRF of patients undergoing colorectal
surgery, we were able to access the status of postopera-
tive nutrition and nutrition recovery [10-13]. Moreover,
by evaluating the serum IgG, IgA, and IgM levels (repre-
senting humoral immunity) [14] and circulating T and
NK cells (representing cellular immunity) [15] in differ-
ent time intervals, we can also assess the levels of post-
operative immune recovery. So in the present study, we
collected and analyzed the nutritional and immunologic
data in our FTMDT trial and aimed to investigate the
exact biochemical roles of the two counterparts (laparos-
copy and fast-track care) in the clinical context.
In this study, we aimed to evaluate prospectively the
biochemical impacts of laparoscopic surgery and fast-
tack care on postoperative nutrition and immune recov-
ery among the colorectal patients. We are also earn to
distinguish the exact role and weight of the two counter-




Our FTMDT trial is a randomized prospective and con-
trolled study with 2 × 2 balanced factorial design. Patients
were enrolled from December 2010 to December 2012.
Patients were randomized into four treatment groups
(1:1:1:1) by means of the randomized numbers generated
by the SPSS 16.0. After written informed consent had
been obtained, patients were randomized to laparoscopyor open surgery and to fast-track or conventional treat-
ment (Figure 1). It generated four groups: (1) laparoscopy
with fast-track treatment (LAFT); (2) open surgery with
fast track treatment (OSFT); (3) laparoscopy with con-




1) American Society of Anesthesiologists (ASA) grades
I–III (no life-threatening systemic diseases)
2) Age ≥18 years old
3) With pathologically confirmed colon and upper
rectal cancer.
Exclusion criteria:
1) Patients are younger than 18 years
2) ASA grade ≥ IV
3) Preoperative evidence of distant metastases
4) History of malignant disease
5) Tumors can be resected by endoscopic mucosal
resection (EMR) or endoscopic submucosal
dissection (ESD), bowel obstruction or perforation,
and patients undergoing total colectomy, mid-low
rectal cancer, and pregnancy.
Ethics
This study was carried out according to the rules of the
Declaration of Helsinki and the CONSORT statement.
The independent medical ethics committee of the par-
ticipating hospital approved the study protocol, with the
approval number: 2010LSY No. 6. The study was regis-
tered under ClinicalTrials.gov: NCT01080547.
Fast-track protocol
The fast-track treatment protocol for colorectal surgery
was well established and reported previously [9]. The
protocol contained oral carbohydrates before surgery,
fluid restriction, body warming, early oral nutrition and
early ambulation, and early removal of nasogastric tube.
Patients were informed about the type of perioperative
treatment but were blinded to the type of surgery. During
the course of FTMDT trial, mechanical bowel preparation
was routinely included in the perioperative treatments for
all colorectal patients. We have described in detail the
protocol of fast-track treatment previously.
Measurements
Surgical information was carefully recorded in detail, in-
cluding surgery types, operation time, and blood loss,
et al. The surgery-associated complications were recorded
postoperatively.
Figure 1 Study flow.
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min, prealbumin, and transferrin levels), humoral im-
munologic factors (circulating IgG, IgM, and IgA levels),
and cellular immunologic factors (circulating T cells and
NK cells). Peripheral blood samples were collected pre-
operatively (baseline) and 12 and 96 h after surgery (in-
dicated as POH12 and POH96, respectively). All blood
samples were taken from peripheral veins and were
transported to the laboratory immediately.
Immune status
Assessment of IgG, IgA, and IgM levels
Quantifications of IgG, IgA, and IgM levels were deter-
mined by Immunological Turbidity Kits for human IgG/
IgA/IgM protein manufactured by Beijing Condor-Teco
Medical Technology Co. Ltd. (Beijing, China).
Assessment of T and NK cell counts
The monoclonal antibodies (CD3-FITC/CD16 + CD56-
PE and CD4-FITC/CD8-PE/CD3-PC5) used for flow cy-
tometric quantification were purchased from Beckman
Coulter, Inc. (Marseille, France). Fluorescent-activated
cell sorting analysis was carried out on the BD FACScan
flow cytometer (Becton, Dickinson and Company, San Jose,
CA, USA) and a minimum of 10,000 cells were assessed
for each detection. After flow cytometric sorting analysis,
CD3+ populations indicate T lymphocytes, and CD3-/
CD16+/CD56+ populations indicate NK lymphocytes.Nutrition status
Assessment of albumin (ALB), PAB, and TRF levels
Serum albumin, PAB, and TRF levels were detected
using N Antiserum to Human Albumin/PAB/TRF Kits
manufactured by Siemens Healthcare Diagnostics Prod-
ucts (Marburg, Germany).Statistical analysis
Data were tabulated on the Excel sheet (Excel 2007 for
Windows; Microsoft Corporation, Redmond, WA, USA)
and then were analyzed using SPSS 16.0 for Windows
(SPSS, Chicago, IL, USA). Numerical variables were pre-
sented as the mean ± SD or percentage of the baseline
level unless otherwise stated. ANOVA, chi-square, and
Kruskal-Wallis tests were applied for data comparison
when appropriate. The repeated measures (two-way
ANOVA) were conducted for analysis of the 2 × 2 fac-
torial design on initial data. P < 0.05 was considered sta-
tistically significant.Results
A total of 92 patients were randomized, and 84 patients fi-
nally finished the study (Figure 1). Twenty-one patients
were randomized for LAFT group, 21 for OSFT, 22 for
LAC, and 20 for OSC. The four groups were balanced with
respect to patients’ characteristics, including sex, age, BMI,
ASA grade, tumor staging, or type of surgery (Table 1).
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All postoperative values (presented in percentage from
baseline) for nutritional status, as well as the mean
values for POH12 and POH96 time intervals, are shown
in Table 2.
As a result, Figure 2 shows three important points: 1)
What is most interesting is that, only in the laparoscopy-
included groups (LAFT and LAC groups), the albumin
level of 96 h (POH96) was higher than that of 12 h
(POH12), indicating the better potency of postoperative
recovery of nutritional status; 2) In the fast-track care-
included groups (OSFT and LAFT groups), the serum al-
bumin level of POH12 and POH96 were both higher than
that in only conventional care-included and same surgery-
type groups (OSC and LAC groups), indicating that fast-
track treatment retards the decrease of postoperative nu-
tritional levels; 3) Albumin levels were highest in the
LAFT group for both POH12 and POH96 time intervals.
Repeated measures (two-way ANOVA) indicated that
the difference of albumin level can be attributed to sur-
gery type and not perioperative treatment. No cross
interaction was found between surgery type and peri-
operative treatment (Table 3).
TRF levels for both POH12 and POH96 time intervals
were highest in the LAFT group and higher in the LAC
group than the other two open surgery groups (Table 2;Table 1 Patients’ baseline characteristics
Characteristics OSC group (n = 20) OSFT group (n
Male sex (%)a 65.00 61.90
Age (years)b 58.0 ± 13.2 59.3 ± 12.5
Body mass index, (kg/m2)b 22.7 ± 3.0 22.7 ± 2.0
Type of surgery, n (%)c
Right hemicolectomy 6 (30.0%) 6 (28.6%)
Left hemicolectomy 3 (15.0%) 4 (19.0%)
Sigmoidectomy 4 (20.0%) 3 (14.3%)
Dixon operation 7 (35.0%) 8 (38.1%)
TNM staging, n (%)c
I 2 (10%) 3 (14.3%)
II 10 (50%) 8 (38.1%)
III 8 (40%) 10 (47.6%)
ASA (%)a
Grade I or II 85.0 81.0
Operating time (minutes)b 137.7 ± 21.8 134.0 ± 23.8
Blood loss (ml)b 172.2 ± 77.1 177.5 ± 92.4
Incision length (cm)b 20.6 ± 2.0 20.9 ± 2.9
ASA indicates American Society of Anaesthesiologists.
Variables were expressed as the mean ± SD.
aChi-square test.
bANOVA test.
cKruskal-Wallis test.Figure 2B). Repeated measures (two-way ANOVA) indi-
cated that the difference of TRF level can be attributed
to surgery type and not perioperative treatment. No
interaction was found between surgery type and peri-
operative treatment (Table 3).
Prealbumin levels were also the highest in the LAFT
group for both POH12 and POH96 time intervals (Table 2;
Figure 2C). But the following two-way ANOVA analysis
that revealed no difference can be found between surgery
type as well as perioperative treatment type (Table 3).
Immunologic status
All postoperative values (presented in percentage from
baseline) for immunologic levels, as well as the mean
values for POH12 and POH96 time intervals, are shown
in Table 2.
As far as the immunologic status after colorectal sur-
gery is concerned, serum IgG/IgA/IgM levels and circu-
lating T/NK cells can be used as parameters for humoral
immunity and cellular immunity, respectively.
Humoral immunity status
Similar with albumin levels, postoperative IgG levels were
also highest in the LAFT group and showed the similar
rank with albumin levels in the four groups (Table 2;
Figure 3A). Another surprising finding was that no matter= 21) LAC group (n = 22) LAFT group (n = 21) P
68.18 57.14 0.895
60.8 ± 7.6 59.1 ± 9.8 0.871
23.8 ± 3.2 23.2 ± 2.6 0.504
0.946
6 (27.3%) 5 (23.8%)
3 (13.6%) 3 (14.3%)
4 (18.2%) 4 (19.0%)
9 (40.9%) 9 (42.9%)
0.995
2 (9.1%) 4 (19.0%)
11 (50%) 7 (33.4%)
9 (40.9%) 10 (47.6%)
86.4 85.7 0.962
193.1 ± 31.5 184.8 ± 43.4 0.000
97.6 ± 53.0 104.7 ± 60.0 0.000
4.5 ± 0.8 4.3 ± 0.7 0.000
Table 2 Postoperative nutritional and immunologic status
Marker Time OSC OSFT LAC LAFT
Albumin POH12 77.3 (62.3–95.9) 81.3 (57.7–107.5) 86.5 (64.9–100.3) 89.0 (66.0–133.8)
POH96 75.9 (56.2–104.8) 80.4 (60.2–109.8) 89.5 (67.0–106.3) 97.3 (76.0–176.9)
Mean 76.6 (11.2) 80.9 (12.9) 88.0 (10.4) 93.1 (20.6)
Prealbumin POH12 76.0 (53.2–101.6) 75.3 (47.8–130.6) 78.8 (54.0–110.6) 80.4 (61.5–100.5)
POH96 68.2 (38.8–124.1) 72.9 (32.6–110.2) 72.9 (33.4–146.6) 75.7 (47.2–110.1)
Mean 72.1 (19.8) 74.1 (18.8) 75.9 (21.0) 78.1 (14.5)
Transferrin POH12 79.5 (65.8–100.0) 81.8 (57.9–100.4) 87.4 (68.9–113.3) 89.3 (50.4–121.4)
POH96 75.6 (53.1–92.8) 82.6 (71.7–113.6) 88.4 (50.5–123.8) 92.0 (62.3–135.2)
Mean 77.6 (11.1) 82.2 (11.1) 87.9 (14.0) 90.7 (19.3)
IgG POH12 82.3 (67.2–100.0) 84.1 (65.6–104.7) 87.6 (72.0–101.3) 88.2 (72.6–101.2)
POH96 82.8 (67.7–114.4) 85.8 (61.8–123.1) 92.7 (70.8–109.0) 94.9 (80.1–121.7)
Mean 82.6 (9.7) 85.0 (12.2) 90.2 (10.1) 91.6 (10.5)
IgA POH12 84.7 (66.5–107.5) 85.8 (63.6–105.9) 88.6 (74.3–106.3) 88.7 (70.3–120.8)
POH96 97.3 (82.7–169.0) 98.1 (66.9–124.6) 95.5 (73.3–111.6) 98.2 (80.1–115.7)
Mean 91.0 (16.2) 92.0 (13.0) 92.1 (11.3) 93.4 (11.6)
IgM POH12 76.9 (52.3–100.0) 79.0 (56.1–122.2) 85.4 (36.9–113.7) 87.6 (49.0–116.0)
POH96 91.6 (86.5–101.2) 90.6 (61.3–179.2) 95.1 (34.5–271.2) 93.1 (64.6–145.9)
Mean 84.3 (20.1) 84.8 (24.3) 90.2 (34.2) 90.3 (17.6)
T cells POH12 88.5 (53.9–171.8) 87.9 (58.8–121.1) 84.6 (53.8–103.4) 86.8 (57.6–128.3)
POH96 91.7 (70.2–128.5) 95.2 (60.8–130.6) 106.2 (57.5–152.9) 102.6 (79.5–126.0)
Mean 90.1 (17.9) 91.6 (19.3) 95.4 (20.9) 94.7 (16.4)
NK cells POH12 113.9 (43.5–314.3) 144.6 (56.2–401.9) 137.0 (90.2–246.0) 147.7 (39.8–324.3)
POH96 88.9 (42.3–338.1) 83.8 (25.2–166.4) 102.1 (43.4–188.9) 97.2 (50.9–158.5)
Mean 101.4 (68.3) 114.2 (74.4) 119.5 (44.4) 122.4 (57.2)
POH12 indicates post-operation 12 h, POH96 indicates post-operation 96 h, and POH12 and POH96 values are presented in percentage from baseline (preoperative
value) for better comparison and range in parentheses.
Mean indicates mean values for POH12 and POH96 time intervals. Mean values are also presented in percentage from baseline and SD in parentheses.
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tained from the fast-track care for the IgG levels were al-
most similar in same surgery-type groups with or without
fast-track care. Repeated measures (two-way ANOVA)
also indicated that the difference of IgG can be attributed
to surgery type and not perioperative treatment (Table 3).
No interaction was found between surgery type and peri-
operative treatment (Table 3).
IgA levels were highest in the LAFT group for both
POH12 and POH96 time intervals, and IgM level was
highest in the LAFT group only for POH12 intervals
(Table 2; Figure 3B, C). But the following repeated mea-
sures (two-way ANOVA) revealed that no difference can
be found between surgery type as well as perioperative
treatment type (Table 3).
Cellular immunity status
T and NK cell counts of POH 96 (Figure 4A, B) were
higher in laparoscopy-included groups (LAC and LAFT)
than that in open surgery-included groups (OSC andOSFT). But the following repeated measures (two-way
ANOVA) revealed that no difference can be found be-
tween surgery type as well as perioperative treatment
type (Table 3).
Operative data and postoperative complications
The laparoscopic surgery-included groups (LAFT and
LAC) exhibit significant differences of longer operation
time, lower blood loss during operation, and shorter inci-
sion length when compared with open surgery-included
groups (OSFT and OSC).
During 3-month follow-up, no differences in postoper-
ative complication rates such as anastomotic leakage,
ileus, and wound infection were observed between the
groups (Table 1).
Discussion
To the best of our knowledge, the exact role of laparoscopic
surgery or fast-track care on both cellular or humoral im-
munity and postoperative nutrition still remains unclear to
Figure 2 Nutritional status of different time intervals in the four groups: albumin (A), TRF (B), prealbumin (C).
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multiple perioperative treatments to attenuate the surgical
stress response and thus accelerates postoperative recovery.
The adoption of laparoscopic colorectal surgery came al-
most coupled with the introduction of FTS. Previous
studies evaluating laparoscopic colorectal cancer surgery
showed benefits of lower morbidity, reduced postoperative
pain, and shortened hospitalization stay [16,17] without
comprising long-term oncological outcomes as compared
to open surgery [2,3].
So, fast-track perioperative care and mini-invasive sur-
gery are both increasingly preferred in the treatment of
colorectal cancer. Many clinical trials [2,3] and meta-
analyses [4,18] had repeatedly shown the benefits of fast-
track perioperative care or laparoscopic surgery for their
short-time outcomes in reducing overall hospital stay
with enhanced recovery of gastrointestinal and pulmon-
ary function and less surgical stress. But most of the
above trials only concerned on the clinical influences of
the fast-track care and laparoscopic surgery, respectively;
extremely few studies were designed to explore the bio-
chemical impacts of the two counterparts on human im-
munologic and nutritional status. The aim of the present
RCT was to evaluate prospectively the nutritional and
immunologic status of the patients in four groups.
We are concerned for a long time about the combined
treatment of laparoscopic colostomy and fast-track care[9,19]. On the 37th ESMO congress, we have reported
the interim analysis of benefits from our FTMDT trial
[20]; and here, we reported our updated and integrated
data. We performed the present 2 × 2 randomized study
of patients undergoing either open or laparoscopic sur-
gery, combined with fast-track perioperative care or con-
ventional treatment. Our results showed that combined
laparoscopic surgery with fast-track care provided best
postoperative recovery of nutritional and immunologic
status as compared to each treatment modality alone.
And the further two-way ANOVA statistic analysis helped
us to distinguish the exact role and weight of the two
counterparts: the earlier recovery of albumin; TRF and
IgG levels can be attributed to surgery type and not peri-
operative treatment (P < 0.05).
Albumin, prealbumin (transthyretin), and transferrin
are commonly called as “hepatic proteins” that are syn-
thesized in the liver and to be used to evaluate nutri-
tional status. Among the three proteins, Serum albumin
has the longest half-life at 18 to 20 days and is most ex-
tensively used as a parameter of nutritional status and as
an indicator of nutritional response to perioperative
treatments [10–13].
What is most interesting in our present study was that,
only in the laparoscopy-included groups (LAFT and
LAC groups), the albumin level of POH96 was higher
than that of POH12, indicating that laparoscopic surgery
Table 3 P values of repeated-measures (two-way ANOVA)
analysis
Marker Variable P
Albumin Surgery types 0.000
Perioperative treatment types 0.065
Cross interactiona 0.696
Prealbumin Surgery types 0.784
Perioperative treatment types 0.671
Cross interaction 0.768
Transferrin Surgery types 0.002
Perioperative treatment types 0.109
Cross interaction 0.837
IgG Surgery types 0.001
Perioperative treatment types 0.419
Cross interaction 0.603
IgA Surgery types 0.503
Perioperative treatment types 0.568
Cross interaction 0.742
IgM Surgery types 0.166
Perioperative treatment types 0.902
Cross interaction 0.601
T cells Surgery types 0.306
Perioperative treatment types 0.999
Cross interaction 0.800
NK cells Surgery types 0.542
Perioperative treatment types 0.647
Cross interaction 0.640
aCross interaction between surgery types (laparoscopy or open surgery) or
perioperative treatment types (fast-track or conventional treatment).
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promoted the recovery of postoperative nutritional status.
Further repeated measures (two-way ANOVA) indicated
that the difference of albumin level can be attributed to
surgery type and not perioperative treatment. That is, fast-
track treatment retarded the drop of postoperative albu-
min level but could not accelerate the albumin level rising
again. Of course, combined laparoscopic surgery with fast-
track treatment provided best postoperative recovery of
nutrition status. Several recent meta-analyses literatures
have indicated that low serum albumin level was also an
independent risk factor for the onset of postoperative
complications and poorer surgical outcome [21,22]. So,
the acceleration of postoperative albumin level recovery
might be translated to the benefits of improved survival
and better outcome.
Why another two hepatic proteins—prealbumin and
transferrin—were not so outstanding and persistent with
albumin in our present study? We assume two possible
reasons for this question: the first is that serum transferrinlevel is determined not only by the nutritional status but
also by the serum iron status, and it can be considered as
a parameter of nutritional status only in the setting of nor-
mal iron level; secondly, prealbumin has the shortest half-
life of 2–3 days. The synthesis of prealbumin can be easily
influenced by the surgical stress, abnormity of liver func-
tion, etc. Therefore, it is less helpful of the three hepatic
proteins for evaluating overall nutritional status. Accord-
ing to recent research by Fujii [23], serum albumin is also
superior to prealbumin for predicting short-term recur-
rence in patients with operable colorectal cancer, which is
an interesting theme needed to be investigated in our
FTMDT trial after long-time follow-up.
As far as the immunologic status are concerned, circu-
lating T and NK cells (representing cellular immunity)
and serum IgG/IgA/IgM levels (representing humoral
immunity) are usually used as the studying parameters.
Representing approximately 75% of serum immunoglob-
ulins in humans, IgG is the most abundant antibody iso-
type found in the circulation, playing a major role in the
immune response to resist malignant cells or infectious
pathogens [24]. T cells (usually express CD3) kill their
target cells by recognizing MHC molecules on the target-
cell membrane and produce a variety of cytokines required
for the activation of other functional cells in the immune
response system. Natural killer cell destroys abnormal tar-
get cells that lack cell-surface MHC class I molecule, such
as infected and malignant cells [25]. Wichmann et al. [15]
have reported fast-track care after colorectal surgery re-
sulted in better-preserved cell-mediated immunity (T cells,
T-helper cells, natural killer cells) when compared with
conventional care. Yang [14] revealed fast-track care im-
proved postoperative humoral immunity (globulin, im-
munoglobulin G, and complement 4) after open colorectal
surgery. In this study, the 2 × 2 randomized LAFA trial in-
dicated that the immune status are quite different in pa-
tients undergoing laparoscopy or open surgery with or
without a fast-track perioperative care, and the im-
munologic level of HLA-DR expression on monocytes
in patients undergoing laparoscopy with fast-track care
remained highest [7]. To the best of our knowledge, the
exact effects of laparoscopic colorectal surgery on both
human cellular and humoral immunity in the context of
FTS have not been studied to date.
Our present study found the beneficial effects of better-
preserved and earlier recovery of humoral immunity sta-
tus (serum IgG level) after colorectal surgery in LAFT
group patients. Repeated measures (two-way ANOVA)
also indicated that the difference of IgG could be attrib-
uted to surgery type and not perioperative treatment. As
for the cellular immunity status, mean Tcells and NK cells
counts were higher in laparoscopy-included groups (LAC
and LAFT) than that in open surgery-included groups
(OSC and OSFT). But the following repeated measures
Figure 3 Humoral immunity status of different time intervals in the four groups: IgG (A), IgA (B), IgM (C).
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type as well as perioperative treatment. Many studies have
reported that the presence of persistent postoperative cir-
culating tumor cells was strongly correlated with a poorer
disease-free and overall survival in colon cancer patients
[26,27], while the better-preserved immunity function
may protect against potential tumor cell growth and seed-
ing [28,29]. So, it is most important to investigate if the
better-preserved immunity function may reduce the oc-
currence of clinical cancer metastasis or recurrence during
the further follow-up study.Figure 4 T (A) and NK cell (B) counts of different time intervals in fouPossible explanation for the better-preserved and earl-
ier recovery of nutritional and immunologic status in
laparoscopy-included groups may be the corresponding
beneficial effects of small incision, reduce of pain, as well as
the early stage physical exercise resulting from the above
two reasons. While the fast-track treatment seems worked
mainly through reducing the stress response of internal
environment and it plays a secondary role peripheral to
laparoscopy as for earlier recovery of nutritional and im-
munologic status after surgery, our biochemical data sug-
gested for the first time the different weights of the twor groups.
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context: laparoscopic surgery may play a more important
role than fast-track treatment in the earlier postoperative
recovery of nutritional and immunologic status.
Conclusions
So, we can draw our conclusions that: 1) Laparoscopic
surgery accelerates postoperative nutrition and humoral
immune levels rise again while fast-track treatment re-
tards the drop of postoperative nutrition and immune
levels; 2) Statistically, the beneficial effects that appeared
in postoperative nutrition and immune status are due to
laparoscopy in excess of fast-track treatment; 3) Com-
bined laparoscopic surgery with fast-track treatment pro-
vides the best postoperative recovery of nutrition and
immune status. So among the colorectal patients, the
mode of laparoscopic resection with fast-track care is the
most optimal treatment, especially in the patients with im-
mune suppression or malnutrition. If only conventional
care can be carried out, laparoscopic surgery should be
recommended to accelerate postoperative recovery.
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